Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: Analysis of the Spanish compassionate use registry in advanced patients

International Journal of Hematology

Volumn 93, Issue 3, 2011, Pages 351-360

  Alegre, Adrián ^a   Aguado, Beatriz ^a   Giraldo, Pilar ^b   Ríos, Eduardo ^c   Cánovas, Araceli ^d   Ibáñez, Ángela ^e   Castillo, Inmaculada ^f   Hernández, Miguel T ^g   Oriol, Albert ^h   Palomera, Luis ⁱ   Rodríguez, Juan N ^j   García, Flor L ^a   Calvo, José M ^k   Martínez Chamorro, Carmen ^l   De La Serna, Javier ^m   Lahuerta, Juan J ^m  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL DE CRUCES   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^f HOSPITAL GENERAL DE ELDA   (Spain)

^g HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^j HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^k HOSPITAL GENERAL DE LANZAROTE   (Spain)

^l Hospital Universitario Quiron   (Spain)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

Compassionate use; Lenalidomide; Multiple myeloma; Plasmacytoma; Salvage therapy

Indexed keywords

ACETYLSALICYLIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BRAIN EDEMA; CANCER GROWTH; CANCER PATIENT; CANCER REGISTRY; CANCER RELAPSE; CANCER SURVIVAL; CROSS-SECTIONAL STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSESTHESIA; EDEMA; FEBRILE NEUTROPENIA; HUMAN; HYPOALBUMINEMIA; JAW OSTEONECROSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MULTIPLE MYELOMA; MYOCLONUS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; RETROSPECTIVE STUDY; SALVAGE THERAPY; SPAIN; STROKE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CROSS-SECTIONAL STUDIES; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SPAIN; SURVIVAL RATE; THALIDOMIDE;

EID: 79955849385     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0785-z     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Piazza FA, Gurrieri C, Trentin L, Semenzato G. Towards a new age in the treatment of multiple myeloma. Ann Hematol. 2007;86:159-72. (Pubitemid 46195988)
3. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209-18. (Pubitemid 47516593)
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. 2009. Last accessed 2009 November 5th; V.2.2010. Available from http://www.nccn.org.
5. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825-31. (Pubitemid 43363369)
6. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-7. (Pubitemid 35217050)
7. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-22. (Pubitemid 38525287)
8. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-32. (Pubitemid 350146107)
9. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, et al. A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. Blood (ASH Annual Meeting Abstracts) 2005;106:1565.
10. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458-64.
11. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2006;6:1165-73. (Pubitemid 44304685)
12. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-42. (Pubitemid 350146108)
13. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22:231-9. (Pubitemid 351250526)
14. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-73. (Pubitemid 44264086)
15. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-57.
16. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-81. (Pubitemid 36962641)
17. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-6. (Pubitemid 46630462)
18. Rosinol L, Cibeira MT, Blade J, Esteve J, Aymerich M, Rozman M, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89:832-6. (Pubitemid 38981343)
19. Calvo-Villas JM, Alegre A, Garcia-Sanchez R, Hernandez MT, Giraldo P, Zudaire M, et al. Efficacy of lenalidomide-based regimens in multiple myeloma complicated by extramedullary plasmacytomas at relapse or progression. Blood (ASH Annual Meeting Abstracts) 2009;114:4952.
20. Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-20.
21. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521-6.
22. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-20.
23. Martinez-Lopez J, Blade J, Gomez del Castillo MC, Mateos MV, Alegre A, Garcia-Larana J, et al. Long term significance of response in multiple myeloma after stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2009;114:1811.
24. Jacobus S, Kumar S, Callander NS, Abonour R, Fonseca R, Siegel D, et al. Effect of venous thrombotic events on overall survival in multiple myeloma: analysis of thrombotic events occurring in E4A03A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma, a trial coordinated by the Eastern Cooperative Oncology Group (ECOG). Blood (ASH Annual Meeting Abstracts) 2008;112:1740.
25. Kumar S, Flinn IW, Hari PN, Callander N, Noga SJ, Stewart AK, et al. Novel three- and four-drug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for newly diagnosed multiple myeloma: encouraging results from the multicenter, randomized, phase 2 EVOLUTION study. Blood (ASH Annual Meeting Abstracts) 2009;114:127.
26. Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009;27:5713-9.
27. Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, et al. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk. 2010;10:138-43.